US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
PL2417156T3
(pl)
|
2009-04-07 |
2015-07-31 |
Roche Glycart Ag |
Trójwartościowe, bispecyficzne przeciwciała
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
RU2573915C2
(ru)
|
2009-09-16 |
2016-01-27 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применение
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
MY166429A
(en)
|
2010-11-17 |
2018-06-26 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
EP2681239B8
(en)
|
2011-02-28 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Antigen binding proteins
|
KR101870555B1
(ko)
|
2011-08-23 |
2018-06-22 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
DK2773671T3
(da)
|
2011-11-04 |
2021-11-15 |
Zymeworks Inc |
Udformning af stabilt heterodimert antistof med mutationer i fc-domænet
|
BR112014018575A2
(pt)
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
GB201203051D0
(en)
*
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203071D0
(en)
*
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
EP2904093B1
(en)
|
2012-10-03 |
2019-04-10 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
RU2015117393A
(ru)
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
CN110669136A
(zh)
|
2012-11-05 |
2020-01-10 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
SG11201503232TA
(en)
|
2012-11-06 |
2015-05-28 |
Medimmune Llc |
Antibodies to s. aureus surface determinants
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
CN105026430A
(zh)
|
2012-11-28 |
2015-11-04 |
酵活有限公司 |
工程化免疫球蛋白重链-轻链对及其用途
|
KR102447350B1
(ko)
|
2013-02-08 |
2022-09-23 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
KR20210094673A
(ko)
|
2013-02-26 |
2021-07-29 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
RU2019108429A
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
|
EP2992011B1
(en)
|
2013-04-29 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
MY172430A
(en)
|
2013-04-29 |
2019-11-25 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
FI3019240T3
(fi)
|
2013-07-09 |
2024-05-30 |
Annexon Inc |
Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä
|
EP3027642B1
(en)
*
|
2013-07-31 |
2020-08-19 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) constructs
|
SG11201601424PA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Site-specific antibody conjugation methods and compositions
|
JP6721505B2
(ja)
*
|
2013-09-05 |
2020-07-15 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
定常領域が修飾された(constant chain modified)二重特異性五価及び六価Ig−M抗体
|
JP6422956B2
(ja)
|
2013-10-11 |
2018-11-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性ドメイン交換共通可変軽鎖抗体
|
US10053511B2
(en)
|
2013-11-06 |
2018-08-21 |
Abbvie Stemcentrx Llc |
Anti-claudin antibodies and methods of use
|
AU2014361856A1
(en)
|
2013-12-12 |
2016-06-30 |
Abbvie Stemcentrx Llc |
Novel anti-DPEP3 antibodies and methods of use
|
BR112016013562A2
(pt)
|
2013-12-20 |
2017-10-03 |
Hoffmann La Roche |
Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
|
EP3960768A1
(en)
|
2014-01-03 |
2022-03-02 |
F. Hoffmann-La Roche AG |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
BR112016015589A2
(pt)
|
2014-01-06 |
2017-10-31 |
Hoffmann La Roche |
módulos de trânsito monovalentes para a barreira hematoencefálica
|
KR20160107190A
(ko)
|
2014-01-15 |
2016-09-13 |
에프. 호프만-라 로슈 아게 |
변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
|
JP2017514143A
(ja)
|
2014-02-21 |
2017-06-01 |
アッヴィ・ステムセントルクス・エル・エル・シー |
メラノーマに使用するための抗dll3抗体および薬物コンジュゲート
|
SG10202107077QA
(en)
|
2014-04-02 |
2021-07-29 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
EP3143043B1
(en)
*
|
2014-05-16 |
2022-12-14 |
Pfizer Inc. |
Bispecific antibodies with engineered ch1-cl interfaces
|
CA3177027A1
(en)
|
2014-05-28 |
2015-12-03 |
Zymeworks Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
MX2016015280A
(es)
|
2014-06-26 |
2017-03-03 |
Hoffmann La Roche |
Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
HUE044814T2
(hu)
|
2014-08-04 |
2019-11-28 |
Hoffmann La Roche |
Bispecifikus, T-sejt-aktiváló antigénkötõ molekulák
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
EP3200829B1
(en)
|
2014-10-01 |
2023-12-06 |
Medimmune, LLC |
Method of conjugating a polypeptide
|
CA2963692A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
JP6951246B2
(ja)
*
|
2014-11-05 |
2021-10-20 |
アネクソン,インコーポレーテッド |
ヒト化抗補体因子C1q抗体及びその使用
|
WO2016071377A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
CN107108720A
(zh)
|
2014-11-06 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
具有改变的FCRN结合的Fc区变体及其使用方法
|
PL3789402T3
(pl)
|
2014-11-20 |
2022-10-17 |
F. Hoffmann-La Roche Ag |
Terapia skojarzona składająca się z dwuswoistych cząsteczek wiążących antygen aktywujących limfocyty T oraz antagonistów wiązania osi PD-1
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
AU2015373910B2
(en)
*
|
2015-01-02 |
2021-11-18 |
Takeda Pharmaceutical Company Limited |
Bispecific antibodies against plasma kallikrein and factor XII
|
CN104628851B
(zh)
*
|
2015-02-12 |
2019-07-30 |
长春百克生物科技股份公司 |
一种抗狂犬病毒的基因工程抗体、其制备方法和应用
|
EP3744732A1
(en)
|
2015-06-24 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Humanized anti-tau(ps422) antibodies and methods of use
|
KR20180021875A
(ko)
*
|
2015-06-30 |
2018-03-05 |
베링거 인겔하임 인터내셔날 게엠베하 |
다중특이적 결합 단백질
|
DK3319993T3
(da)
|
2015-07-10 |
2020-04-20 |
Genmab As |
AXL-SPECIFIKKE antistof-lægemiddelkonjugater til kræftbehandling
|
IL257047B1
(en)
|
2015-07-21 |
2024-07-01 |
Dyax Corp |
A monoclonal antibody that inhibits factor XIIA
|
WO2017034770A1
(en)
|
2015-08-26 |
2017-03-02 |
Bison Therapeutics Inc. |
Multispecific antibody platform and related methods
|
CN106519024A
(zh)
*
|
2015-09-15 |
2017-03-22 |
三生国健药业(上海)股份有限公司 |
一种用于去除单克隆抗体中异构体的复性液及复性方法
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
CN108139394B
(zh)
|
2015-10-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
用于确定同时结合的基于细胞的fret测定法
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
LT3356411T
(lt)
|
2015-10-02 |
2021-09-10 |
F. Hoffmann-La Roche Ag |
Bispecifiniai antikūnai, specifiniai pd1 ir tim3
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
CN107949574A
(zh)
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
AR106365A1
(es)
|
2015-10-02 |
2018-01-10 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
CA2990755A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffman-La Roche Ag |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
EP3913000A1
(en)
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
KR20180069839A
(ko)
|
2015-10-08 |
2018-06-25 |
자임워크스 인코포레이티드 |
카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
|
EP4015533A1
(en)
|
2015-10-29 |
2022-06-22 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
IL296130A
(en)
|
2015-11-24 |
2022-11-01 |
Annexon Inc |
Anti-complement factor c1q fab fragments and their uses
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
CA2997406C
(en)
|
2015-12-09 |
2024-05-28 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
BR112018015259A2
(pt)
|
2016-01-27 |
2018-12-18 |
Medimmune Llc |
métodos para preparação de anticorpos com um padrão de glicosilação definido
|
CN109153728A
(zh)
|
2016-03-21 |
2019-01-04 |
埃尔斯塔治疗公司 |
多特异性和多功能分子及其用途
|
HRP20230528T1
(hr)
|
2016-03-22 |
2023-08-04 |
F. Hoffmann - La Roche Ag |
Bispecifične molekule t stanica aktivirane proteazom
|
CN109071635B
(zh)
|
2016-05-02 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Contorsbody-单链靶标结合物
|
AR108377A1
(es)
*
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
CN109475627B
(zh)
*
|
2016-05-26 |
2023-01-06 |
齐鲁普吉湾生物治疗公司 |
抗体混合物
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
CA3059010A1
(en)
|
2016-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
CN109415435B
(zh)
|
2016-07-04 |
2024-01-16 |
豪夫迈·罗氏有限公司 |
新型抗体形式
|
CN118005799A
(zh)
*
|
2016-09-23 |
2024-05-10 |
马伦戈治疗公司 |
包含λ轻链和κ轻链的多特异性抗体分子
|
WO2018060035A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Spr-based dual-binding assay for the functional analysis of multispecific molecules
|
EP3519437B1
(en)
|
2016-09-30 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Bispecific antibodies against p95her2
|
CA3041254A1
(en)
|
2016-10-19 |
2018-04-26 |
Invenra Inc. |
Antibody constructs
|
MA46700A
(fr)
|
2016-11-01 |
2021-05-19 |
Genmab Bv |
Variants polypeptidiques et ses utilisations
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
AU2018218345A1
(en)
|
2017-02-10 |
2019-08-29 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
JP7116736B2
(ja)
*
|
2017-03-02 |
2022-08-10 |
ノバルティス アーゲー |
操作されたヘテロ二量体タンパク質
|
SG11201908127WA
(en)
|
2017-03-10 |
2019-10-30 |
Hoffmann La Roche |
Method for producing multispecific antibodies
|
KR20200074915A
(ko)
|
2017-03-31 |
2020-06-25 |
젠맵 홀딩 비.브이. |
이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법
|
CA3056600A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Ignacio Moraga GONZALEZ |
Synthekine compositions and methods of use
|
JP7247101B2
(ja)
|
2017-04-03 |
2023-03-28 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Steap-1に結合する抗体
|
KR20190121816A
(ko)
|
2017-04-03 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
CN110382525B
(zh)
|
2017-04-03 |
2023-10-20 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
SG11201909154SA
(en)
|
2017-04-05 |
2019-10-30 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
AU2018250875A1
(en)
|
2017-04-13 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
MA49259A
(fr)
|
2017-06-07 |
2020-04-15 |
Genmab Bv |
Anticorps thérapeutiques à base d'hexamères d'igg mutées
|
UY37758A
(es)
*
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
CN110831978A
(zh)
|
2017-06-30 |
2020-02-21 |
酵活有限公司 |
稳定的嵌合fab
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
WO2019014912A1
(zh)
*
|
2017-07-21 |
2019-01-24 |
赵磊 |
一种异二聚体蛋白及其制备方法
|
CN113896797B
(zh)
|
2017-08-01 |
2023-05-09 |
Ab工作室有限公司 |
双特异性抗体及其用途
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
AU2018338859A1
(en)
*
|
2017-09-29 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
MX2020003497A
(es)
|
2017-10-20 |
2020-07-22 |
Hoffmann La Roche |
Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
AU2018358883A1
(en)
|
2017-10-30 |
2020-04-23 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
BR112020008031A2
(pt)
|
2017-11-01 |
2020-10-27 |
F. Hoffmann-La Roche Ag |
anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Compボディ−多価標的結合物質
|
US20210324108A1
(en)
|
2017-11-01 |
2021-10-21 |
Hoffmann-La Roche Inc. |
Bispecific 2+1 contorsbodies
|
BR112020011469A2
(pt)
|
2017-12-21 |
2020-11-24 |
F. Hoffmann-La Roche Ag |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
|
US11945839B2
(en)
|
2017-12-22 |
2024-04-02 |
Hoffmann-La Roche Inc. |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
EP3743440A1
(en)
|
2018-01-24 |
2020-12-02 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
CA3088355A1
(en)
|
2018-02-06 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
CA3089287A1
(en)
|
2018-02-08 |
2019-08-15 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019201892A1
(en)
|
2018-04-17 |
2019-10-24 |
Universität Heidelberg |
Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising nc-1-fc
|
US20210163594A1
(en)
*
|
2018-04-17 |
2021-06-03 |
Invenra Inc. |
Binding molecules
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
SG11202010601VA
(en)
|
2018-05-03 |
2020-11-27 |
Genmab Bv |
Antibody variant combinations and uses thereof
|
WO2019220369A2
(en)
|
2018-05-16 |
2019-11-21 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
|
MX2020013348A
(es)
*
|
2018-06-09 |
2021-03-09 |
Boehringer Ingelheim Int |
Anticuerpos biespecificos contra dll3-cd3.
|
JP7513530B2
(ja)
|
2018-06-22 |
2024-07-09 |
ジェンマブ ホールディング ビー.ブイ. |
抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
SG11202012993SA
(en)
|
2018-07-13 |
2021-02-25 |
Genmab As |
Variants of cd38 antibody and uses thereof
|
JP2021526845A
(ja)
|
2018-07-13 |
2021-10-11 |
ゲンマブ エー/エス |
Cd38抗体を使用したトロゴサイトーシスを介した治療
|
MA53812A
(fr)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
|
CN112955240B
(zh)
*
|
2018-10-25 |
2022-09-16 |
豪夫迈·罗氏有限公司 |
抗体FcRn结合的修饰
|
KR102467349B1
(ko)
|
2018-10-29 |
2022-11-16 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
KR20210124959A
(ko)
|
2018-11-06 |
2021-10-15 |
젠맵 에이/에스 |
항체 제제
|
JP2022513708A
(ja)
|
2018-12-05 |
2022-02-09 |
モルフォシス・アーゲー |
多重特異性抗原結合分子
|
TWI829831B
(zh)
|
2018-12-21 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合cd3之抗體
|
EP3674319A1
(en)
|
2018-12-24 |
2020-07-01 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
WO2020136564A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
EP3674316A1
(en)
|
2018-12-24 |
2020-07-01 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
KR20210108421A
(ko)
|
2018-12-24 |
2021-09-02 |
사노피 |
돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질
|
JP2022515473A
(ja)
|
2018-12-28 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
免疫応答が増幅された患者における治療的使用のためのペプチド-mhc-i-抗体融合タンパク質
|
WO2020138487A1
(ja)
|
2018-12-28 |
2020-07-02 |
協和キリン株式会社 |
TfRに結合するバイスペシフィック抗体
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
***新抗原及其用途
|
JP2022522662A
(ja)
|
2019-02-21 |
2022-04-20 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
AU2020226904A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
JP2022521937A
(ja)
|
2019-02-21 |
2022-04-13 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
EP3948281A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Spr-based binding assay for the functional analysis of multivalent molecules
|
EP3947440A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Method for generating avid-binding multispecific antibodies
|
AU2020263910A1
(en)
|
2019-04-25 |
2021-10-21 |
F. Hoffmann-La Roche Ag |
Activatable therapeutic multispecific polypeptides with extended half-life
|
CN113924314A
(zh)
|
2019-04-25 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
通过多肽链交换活化的治疗性多特异性多肽
|
JP2022531128A
(ja)
|
2019-04-25 |
2022-07-06 |
エフ.ホフマン-ラ ロシュ アーゲー |
ポリペプチド鎖交換による抗体由来ポリペプチドの生成
|
WO2020225456A1
(en)
|
2019-05-09 |
2020-11-12 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
WO2020229378A1
(en)
|
2019-05-13 |
2020-11-19 |
F. Hoffmann-La Roche Ag |
Interference-suppressed pharmacokinetic immunoassay
|
BR112021025425A2
(pt)
|
2019-06-19 |
2022-02-01 |
Hoffmann La Roche |
Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre
|
JP7450647B2
(ja)
|
2019-06-26 |
2024-03-15 |
エフ. ホフマン-ラ ロシュ アーゲー |
Sirt-1遺伝子ノックアウトを有する哺乳類細胞株
|
TW202115115A
(zh)
|
2019-07-02 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
免疫結合物
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
JP2022541332A
(ja)
|
2019-07-26 |
2022-09-22 |
ヤンセン バイオテツク,インコーポレーテツド |
カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
CN114174342A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
MX2022001799A
(es)
|
2019-08-15 |
2022-03-11 |
Janssen Biotech Inc |
Materiales y metodos para fragmentos variables de cadena unica mejorados.
|
US20210077697A1
(en)
*
|
2019-09-12 |
2021-03-18 |
Fresenius Medical Care Deutschland Gmbh |
System and method for connecting a concentrate container with a blood treatment device without leakages
|
EP4055046A1
(en)
|
2019-11-06 |
2022-09-14 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
KR20220113791A
(ko)
|
2019-12-18 |
2022-08-16 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
MX2022007635A
(es)
|
2019-12-18 |
2022-07-19 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4.
|
CA3171363A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Kisoji Biotechnology Inc. |
Polypeptides, protein complexes and method for making same
|
WO2021136772A1
(en)
|
2020-01-02 |
2021-07-08 |
F. Hoffmann-La Roche Ag |
Method for determining the amount of a therapeutic antibody in the brain
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
AU2021208532A1
(en)
|
2020-01-16 |
2022-07-07 |
Genmab A/S |
Formulations of CD38 antibodies and uses thereof
|
CN115697388A
(zh)
|
2020-01-30 |
2023-02-03 |
优莫佳生物制药股份有限公司 |
双特异性转导增强子
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
IL302351A
(en)
|
2020-03-13 |
2023-06-01 |
Janssen Biotech Inc |
Materials and methods for binding SIGLEC-3/CD33
|
WO2021209402A2
(en)
|
2020-04-15 |
2021-10-21 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
WO2021217085A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
JP2023524068A
(ja)
|
2020-04-30 |
2023-06-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
サイトカイン関連有害事象を治療する方法
|
WO2021231278A1
(en)
|
2020-05-11 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Combination therapy with modified pbmcs and an immunoconjugate
|
MX2022014938A
(es)
|
2020-05-27 |
2023-03-06 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
|
PE20230470A1
(es)
|
2020-06-19 |
2023-03-14 |
Hoffmann La Roche |
Moleculas de union al dominio fc de activacion inmunitaria
|
CN115916826A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
与CD3和FolR1结合的抗体
|
US11780920B2
(en)
|
2020-06-19 |
2023-10-10 |
Hoffmann-La Roche Inc. |
Antibodies binding to CD3 and CD19
|
AR122658A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
WO2022018294A1
(en)
|
2020-07-23 |
2022-01-27 |
Genmab B.V. |
A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
US11827708B2
(en)
|
2020-07-29 |
2023-11-28 |
Janssen Biotech, Inc. |
Proteins comprising HLA-G antigen binding domains and their uses
|
WO2022046922A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
JP2023540248A
(ja)
|
2020-08-26 |
2023-09-22 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Trbc1またはtrbc2を検出する方法
|
CA3190755A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
IL301366A
(en)
|
2020-09-24 |
2023-05-01 |
Hoffmann La Roche |
Mammalian cell lines with genetic knockout
|
AU2021351187A1
(en)
|
2020-10-02 |
2023-04-20 |
Genmab A/S |
Antibodies capable of binding to ROR2 and bispecific antibodies binding to ROR2 and CD3
|
IL301956A
(en)
*
|
2020-10-07 |
2023-06-01 |
Dren Bio Inc |
Antibodies against dectin-1 and methods of using them
|
AR123767A1
(es)
|
2020-10-13 |
2023-01-11 |
Janssen Biotech Inc |
Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii
|
IL302277A
(en)
|
2020-10-22 |
2023-06-01 |
Janssen Biotech Inc |
Proteins containing delta-like ligand antigen binding domains (DLL3) and uses thereof
|
WO2022103773A1
(en)
*
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
KR20230107305A
(ko)
|
2020-11-10 |
2023-07-14 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도
|
US20240027436A1
(en)
*
|
2020-11-12 |
2024-01-25 |
Northwestern University |
Cell-free expression of antibodies, antigen-binding fragments thereof, and antibody derivatives
|
CN114539413A
(zh)
*
|
2020-11-25 |
2022-05-27 |
三生国健药业(上海)股份有限公司 |
结合her2的多价双特异性抗体、其制备方法和用途
|
KR20230120665A
(ko)
|
2020-12-17 |
2023-08-17 |
에프. 호프만-라 로슈 아게 |
항-hla-g 항체 및 이의 용도
|
JP2023553692A
(ja)
|
2020-12-18 |
2023-12-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
標的治療のための前駆体タンパク質及びキット
|
CN116670282A
(zh)
|
2020-12-22 |
2023-08-29 |
豪夫迈·罗氏有限公司 |
靶向xbp1的寡核苷酸
|
JP2024503826A
(ja)
|
2021-01-06 |
2024-01-29 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1-lag3二重特異性抗体及びcd20 t細胞二重特異性抗体を用いる併用療法
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
WO2022170305A1
(en)
*
|
2021-02-05 |
2022-08-11 |
Phanes Therapeutics, Inc. |
Bispecific antibodies with charge pairs and uses thereof
|
WO2022175217A1
(en)
|
2021-02-18 |
2022-08-25 |
F. Hoffmann-La Roche Ag |
Method for resolving complex, multistep antibody interactions
|
AR125212A1
(es)
|
2021-03-24 |
2023-06-28 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
|
CN116897159A
(zh)
|
2021-03-31 |
2023-10-17 |
江苏恒瑞医药股份有限公司 |
截短的taci多肽及其融合蛋白和用途
|
JP2024515591A
(ja)
|
2021-04-08 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Tcrに結合する多機能性分子およびその使用
|
JP2024515301A
(ja)
*
|
2021-04-20 |
2024-04-08 |
アムジエン・インコーポレーテツド |
多重特異性及び一価のigg分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
CA3217803A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
KR20240006586A
(ko)
|
2021-05-12 |
2024-01-15 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
|
WO2022237882A1
(zh)
|
2021-05-14 |
2022-11-17 |
江苏恒瑞医药股份有限公司 |
一种抗原结合分子
|
KR20240021859A
(ko)
|
2021-06-18 |
2024-02-19 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
WO2023279092A2
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
WO2023284829A1
(zh)
|
2021-07-14 |
2023-01-19 |
江苏恒瑞医药股份有限公司 |
特异性结合hgfr和egfr的抗原结合分子及其医药用途
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
AU2022318255A1
(en)
|
2021-07-27 |
2024-01-18 |
Morphosys Ag |
Combinations of antigen binding molecules
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
EP4377351A1
(en)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer
|
IL311141A
(en)
|
2021-09-06 |
2024-04-01 |
Genmab As |
Antibodies capable of binding to CD27, their variants and uses thereof
|
WO2023037333A1
(en)
|
2021-09-13 |
2023-03-16 |
Janssen Biotech, Inc |
CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
|
CA3232472A1
(en)
|
2021-09-23 |
2023-03-30 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-klb antibodies and uses
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
CN117916273A
(zh)
|
2021-09-30 |
2024-04-19 |
江苏恒瑞医药股份有限公司 |
抗il23抗体融合蛋白及用途
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
AU2022384597A1
(en)
|
2021-11-10 |
2024-06-13 |
Astrazeneca Ab |
Antibody molecules and conjugates
|
AU2022392829A1
(en)
|
2021-11-22 |
2024-07-11 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
WO2023094282A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Quantification of low amounts of antibody sideproducts
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023175064A1
(en)
|
2022-03-17 |
2023-09-21 |
Astrazeneca Ab |
Methods for purifying bispecific antibodies
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2024002938A1
(en)
|
2022-06-27 |
2024-01-04 |
Astrazeneca Ab |
Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
WO2024017371A1
(zh)
*
|
2022-07-22 |
2024-01-25 |
信达生物制药(苏州)有限公司 |
促进多特异性抗体的重链和轻链同源配对的突变体
|
TW202412859A
(zh)
|
2022-07-28 |
2024-04-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及雙特異性檢查點抑制劑之組合
|
CN117820490A
(zh)
*
|
2022-09-28 |
2024-04-05 |
科兴生物制药股份有限公司 |
Vegf和ang-2双特异性抗体及其应用
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
WO2024095173A1
(en)
|
2022-11-02 |
2024-05-10 |
Janssen Biotech, Inc. |
Methods of treating cancers
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024104988A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with activatable effector domain
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
WO2024107752A2
(en)
|
2022-11-15 |
2024-05-23 |
Onestone Therapeutics Llc |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|